SCHEMBL6484538

SCHEMBL6484538

CCN(CC)c1ccc(CCCc2ccc(Nc3ccc(OC)cc3C(=O)O)cc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.58
LMNA P02545 3/20 0.58
KMT2A Q03164 3/20 0.58
MAPT P10636 2/20 0.58
POLB P06746 1/20 0.58
PLK1 P53350 1/20 0.53
PLK3 Q9H4B4 1/20 0.53
AKR1C3 P42330 14/20 0.51
AKR1C2 P52895 14/20 0.51
HPGD P15428 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
GFER P55789 1/20 0.50
CTSV O60911 1/20 0.48
CTSL P07711 1/20 0.48
ALDH1A1 P00352 1/20 0.43
GAA P10253 1/20 0.43
ALOX12 P18054 1/20 0.43
MAPK1 P28482 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6474913 0.82 MEN1 (0.55) MEN1LMNAKMT2AMAPTPLK1
SCHEMBL6481662 0.81 CTSV (0.58) MEN1LMNAKMT2AMAPTAKR1C3
SCHEMBL6475709 0.81 MAPT (0.43) MEN1LMNAKMT2AMAPTPOLB
SCHEMBL6475025 0.80 MEN1 (0.65) MEN1LMNAKMT2AMAPTPOLB
SCHEMBL9593627 0.79 MEN1 (0.83) MEN1LMNAKMT2AMAPTPOLB
SCHEMBL6474231 0.78 MAPT (0.56) MEN1LMNAKMT2AMAPTPOLB
SCHEMBL6474928 0.77 SIRT1 (0.50) MEN1KMT2APLK1PLK3AKR1C3
SCHEMBL6475576 0.77 MAPT (0.46) MEN1LMNAKMT2AMAPTPOLB
SCHEMBL6474259 0.77 MEN1 (0.60) MEN1LMNAKMT2AMAPTPOLB
SCHEMBL6474530 0.77 MEN1 (0.68) MEN1LMNAKMT2AMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6972287-B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits PFIZER INC. (US) 2005-12-06 US claimed
EP-1225886-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2002-07-31 EP claimed
WO-2000076489-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2000-12-21 WO claimed
US-6972287-B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits PFIZER INC. (US) 2005-12-06 US disclosed
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-11-04 US disclosed
EP-1225886-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2002-07-31 EP disclosed
WO-2000076489-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits APP, PSEN1, BACE1 MEN1 474/4885LMNA 876/4885KMT2A 4729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.